TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19324346

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) 6-g bolus IV followed by 2 g/h baseline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy nonpregnant women
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pregnant control women (HP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: General health of infants born to preeclamptic mothers given MgSO4
Number of subjects: 42
Study: 17868489

Group type: EXPERIMENTAL
Intervention: LoBAG30 diet (30% protein, 50% fat, 30% carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard diet (15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 8
Study: 15766334

Group type: EXPERIMENTAL
Intervention: Apfel et al.'s scoring system
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Koivuranta et al.'s scoring system
Number of subjects: 1388
Study: 12495098

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infusion at 2 mL/hr for 48 hours plus PCA morphine
Number of subjects: 52

Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 52
Study: 10622581

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) alone at standard dosage (3 MU t.i.w.) for 12 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ribavirin as single therapy at standard dosage (15 mg/kg bodyweight in two divided doses daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ribavirin in combination with interferon alpha at standard doses for 6-12 months
Number of subjects: 150
Study: 7749168

Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) monotherapy
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Navoban + dexamethasone
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Navoban
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Navoban + corticosteroid
Number of subjects: 1050
Study: 2405323

Group type: COMPARATOR
Intervention: Clindamycin phosphate alone (N = 23)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate plus tobramycin (N = 28)
Number of subjects: 51
Study: 161170

Group type: EXPERIMENTAL
Intervention: 40 microgram ipratropium bromide (I)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 400 microgram fenoterol (F)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both drugs in combination (IF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study: 31927026

Group type: EXPERIMENTAL
Intervention: Simethicone 160 mg with 50 mL water, administered 2-8 hours before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simethicone group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 30636701

Group type: EXPERIMENTAL
Intervention: 25 mg methylcobalamin
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 50 mg methylcobalamin
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 28502083

Group type: EXPERIMENTAL
Intervention: Dynamic optical coherence tomography (D‐OCT)
Number of subjects: 47
Study: 27281727

Group type: EXPERIMENTAL
Intervention: 20 mL interscalene nerve block
Number of subjects: 154

Group type: COMPARATOR
Intervention: 40 mL interscalene nerve block
Number of subjects: 154
Study: 24679400

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended-release
Number of subjects: 1008
Study: 21931122

Group type: EXPERIMENTAL
Intervention: Paricalcitol (IV or oral depending on site)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 272
Study: 20032789

Group type: EXPERIMENTAL
Intervention: PCB + S (25 mg daily, 2 weeks on, 1 week off)
Number of subjects: 56

Group type: COMPARATOR
Intervention: PCB (15 mg/kg every 3 weeks)
Number of subjects: 56
Study: 18722318

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control
Number of subjects: 453
Study: 15957562

Group type: EXPERIMENTAL
Intervention: Pure group condition (problem-solving skills training with all members having conduct problems)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Mixed group condition (problem-solving skills training with adolescents with and without behavior problems)
Number of subjects: 139
Study: 12204648

Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (HeNe, 632.8 nm) with a dose of 30 J/cm²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham irradiation (placebo)
Number of subjects: 0
Study: 10494759

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with targeted INR of 2.0 to 2.5
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with targeted INR of 1.5 to 1.9
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8610715

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Metaproterenol (5% solution, 15 mg)
Number of subjects: 213
Study: 1487306

Group type: EXPERIMENTAL
Intervention: Partner-specific leukocyte immunotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Own cells immunotherapy
Number of subjects: 51
Study: 4035297

Group type: EXPERIMENTAL
Intervention: Oral water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exogenous infusions of porcine motilin (physiological and pharmacological)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 0
Study: 31601166

Group type: EXPERIMENTAL
Intervention: Lack of adequate knowledge of infection control procedures and disease transmission
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Non-compliance with infection control protocol of vaccination against hepatitis B virus
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Attending 12 or less number of patients daily
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Working in dental clinics without an infection control unit
Number of subjects: 450
Study: 29549030

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 27114561

Group type: EXPERIMENTAL
Intervention: Adalimumab plus Methotrexate (ADA + MTX)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo plus Methotrexate (PBO + MTX)
Number of subjects: 444
Study: 24333035

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 24957431

Group type: EXPERIMENTAL
Intervention: Patients with DM but not DR (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diabetic patients with nonproliferative DR (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diabetic patients with proliferative DR (Group 4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients without DM (Group 1)
Number of subjects: 60
Study: 22207723

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 21
Study: 19589288

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with Lavonase system (250 mL saline solution sac, twice daily for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal syringe (10 mL saline solution, 3 times daily for 14 days)
Number of subjects: 20
Study: 17322603

Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Latoprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xalatan (after crossover from Latoprost)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Latoprost (after crossover from Xalatan)
Number of subjects: 30
Study: 15257726

Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 128
Study: 11190792

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quiet rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnosis (during physical challenges)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 0
Study: 9825507

Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 18 kD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 38 kD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 18 kD and 38 kD
Number of subjects: 0
Study: 7503405

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: budesonide
Number of subjects: 17
Study: 1955814

Group type: EXPERIMENTAL
Intervention: Diazepam (0 mg, 7.5 mg, 15 mg, 30 mg/70 kg, p.o.)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Triazolam (0 mg, 0.375 mg, 0.75 mg/70 kg, p.o.)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Observing contingency present
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Observing contingency with increased error requirements
Number of subjects: 3
Study: 7134226

Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indobufen (both dosages)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indobufen (higher dosage)
Number of subjects: 12
Study: 31575571

Group type: EXPERIMENTAL
Intervention: Active behavioural physiotherapy intervention (ABPI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard physiotherapy intervention
Number of subjects: 60
Study: 27832646

Group type: EXPERIMENTAL
Intervention: Multinutrient supplementation (PROfertil® female) including folic acid, selenium, vitamin E, catechins, glycyrrhizin, diosgenin, damiana, omega‐3‐fatty acids; n = 50
Number of subjects: 100

Group type: COMPARATOR
Intervention: 400 µg folic acid (control group); n = 50
Number of subjects: 100
Study: 25301018

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) tools
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patient knowledge of medical condition and treatment options
Number of subjects: 123
Study: 24144885

Group type: EXPERIMENTAL
Intervention: PICD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional ICD
Number of subjects: 10
Study: 22532053

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 20000066

Group type: EXPERIMENTAL
Intervention: Iron-zinc supplementation
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control Group (Iron-only supplementation)
Number of subjects: 156
Study: 17516966

Group type: EXPERIMENTAL
Intervention: Lactulose alone (n = 77)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lactulose combined with ispaghula husk (Fybogel group, n = 70)
Number of subjects: 147
Study: 15161357

Group type: EXPERIMENTAL
Intervention: Chronic low-dose whole-body ionizing radiation exposure
Number of subjects: 45468
Study: 11394601

Group type: EXPERIMENTAL
Intervention: Exercise (running for 15 minutes on a neutral-incline treadmill)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the state before exercise)
Number of subjects: 103
Study: 9546804

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and didanosine (ddI) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8296698

Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: nitrates
Number of subjects: 15

Group type: COMPARATOR
Intervention: no therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: atenolol and diltiazem
Number of subjects: 15
Study: 1707338

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Concomitant radiation therapy and chemotherapy (RT + CT) with 5‐fluorouracil (5‐FU), mitomycin C, and bleomycin
Number of subjects: 59
Study: 7009256

Group type: EXPERIMENTAL
Intervention: Conventional oxprenolol administered twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol administered once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclopenthiazide 0.5 mg daily (in 16 patients)
Number of subjects: 20
Study: 31790344

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus best supportive care (BSC)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 30679138

Group type: EXPERIMENTAL
Intervention: Lipiodol plus IVF
Number of subjects: 70

Group type: COMPARATOR
Intervention: IVF alone
Number of subjects: 70
Study: 27822982

Group type: EXPERIMENTAL
Intervention: Thermal protective clothing (TPC) and self‐contained breathing apparatus (SCBA) during exertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-stressed conditions (without TPC and SCBA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two different SCBA cylinder masses
Number of subjects: 0
Study: 25386670

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study: 23356829

Group type: COMPARATOR
Intervention: Pelvic drainage removed on postoperative day 1 (Group 2)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Pelvic drainage removed on postoperative day 7 (Group 1)
Number of subjects: 331

Group type: COMPARATOR
Intervention: No drainage (Group 3)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Robot-assisted radical prostatectomy without drainage (Group 4)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Open RRP (Groups 1-3)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Robot-assisted RARP (Group 4)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Nodal-positive patients
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Nodal-negative patients
Number of subjects: 331
Study: 21249381

Group type: EXPERIMENTAL
Intervention: Pleuran (β-glucan from Pleurotus ostreatus)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19742334

Group type: EXPERIMENTAL
Intervention: Fast track surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (traditional surgery)
Number of subjects: 92
Study: 17535530

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 48
Study: 15581263

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received during all three years (FYs 2000, 2001, and 2002)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received in FY 2002 only
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received in FYs 2001 and 2002
Number of subjects: 976

Group type: COMPARATOR
Intervention: No self-monitoring of blood glucose (SMBG) with monitoring strips
Number of subjects: 976
Study: 11270701

Group type: EXPERIMENTAL
Intervention: CapSure Z lead (5034 bipolar)
Number of subjects: 89

Group type: COMPARATOR
Intervention: CapSure SP lead (5024 bipolar)
Number of subjects: 89
Study: 9709721

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 23-valent vaccine only
Number of subjects: 0
Study: 8049040

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and/or tympanostomy tube insertion
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Consulting an ear, nose, and throat specialist
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Parental exaggeration of the episodes
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Having the first episode under 6 months of age
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Recurrent respiratory tract infections
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Urban domicile
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 2512
Study: 3276900

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with 5‐fluorouracil, semustine, and vincristine (MOF) (187 patients)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (4,600‐4,700 rad in 26‐27 fractions; 5,100‐5,300 rad maximum at the perineum) (184 patients)
Number of subjects: 555

Group type: COMPARATOR
Intervention: No further treatment (184 patients)
Number of subjects: 555
Study: 31674929

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 63
Study: 28729021

Group type: EXPERIMENTAL
Intervention: Ceritinib 450 mg with food
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ceritinib 600 mg with food
Number of subjects: 137

Group type: COMPARATOR
Intervention: Ceritinib 750 mg fasted
Number of subjects: 137
Study: 26183691

Group type: EXPERIMENTAL
Intervention: Cardiovascular Group (CVG; n=20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Resistance Group (RG; n=20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (CG; n=20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postural Group (PG; n=20)
Number of subjects: 80
Study: 23597539

Group type: EXPERIMENTAL
Intervention: Near-infrared light device
Number of subjects: 60
Study: 21668683

Group type: EXPERIMENTAL
Intervention: Ann Arbor strain live attenuated influenza vaccine (LAIV)
Number of subjects: 4245
Study: 18269652

Group type: EXPERIMENTAL
Intervention: Erythromycin + gentamicin + nystatin sulfate orally (Group A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 91
Study: 16528432

Group type: EXPERIMENTAL
Intervention: home-based intervention program
Number of subjects: 121
Study: 14710913

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11151578

Group type: EXPERIMENTAL
Intervention: Angled abutments (0 to 15 degrees)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Angled abutments (20 to 45 degrees)
Number of subjects: 467
Study: 8935222

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1392444

Group type: EXPERIMENTAL
Intervention: Urodilatin (CDD/ANP‐95‐126) administered in a long‐term, low‐dose infusion (6‐20 ng/kg bw.min) for 96 hours after HTx
Number of subjects: 51
Study: 4057974

Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 3
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 4
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 5
Number of subjects: 6
Study: 30987415

Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of 5 ml 1% ropivacaine before and after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraperitoneal instillation of 20 ml 0.5% ropivacaine after induction of pneumoperitoneum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of 5 ml 1% ropivacaine
Number of subjects: 60
Study: 29022100

Group type: EXPERIMENTAL
Intervention: Sea buckthorn
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Strawberry
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 27304841

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25144296

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg and Candesartan cilexetil 32 mg
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (any dose) and Candesartan cilexetil (any dose)
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg and Candesartan cilexetil 4 mg
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Nifedipine GITS monotherapy
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS plus Candesartan cilexetil combination therapy
Number of subjects: 1381
Study: 22350244

Group type: EXPERIMENTAL
Intervention: Laparoscopic CBD exploration
Number of subjects: 256

Group type: COMPARATOR
Intervention: Open CBD exploration
Number of subjects: 256
Study: 20067715

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (0.20 mJ/mm(2))
Number of subjects: 39

Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (0.17 mJ/mm(2))
Number of subjects: 39
Study: 17530270

Group type: EXPERIMENTAL
Intervention: Lignocaine (2%) with adrenaline (1:80,000)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lignocaine (2%)
Number of subjects: 30
Study: 16123708

Group type: EXPERIMENTAL
Intervention: GuttaFlow (GF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: conventional cold laterally condensed gutta‐percha (LC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: warm vertically condensed gutta‐percha (VC)
Number of subjects: 90